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Abstract
Background: Saturated fatty acid-rich high fat (HF) diets trigger abdominal adiposity, insulin resistance, type 2
diabetes and cardiac dysfunction. This study was aimed at evaluating the effects of nascent obesity on the cardiac
function of animals fed a high-fat diet and at analyzing the mechanisms by which these alterations occurred at the
level of coronary reserve.
Materials and methods: Rats were fed a control (C) or a HF diet containing high proportions of saturated fatty acids
for 3 months. Thereafter, their cardiac function was evaluated in vivo using a pressure probe inserted into the cavity of
the left ventricle. Their heart was isolated, perfused iso-volumetrically according to the Langendorff mode and the
coronary reserve was evaluated by determining the endothelial-dependent (EDV) and endothelial-independent (EIV)
vasodilatations in the absence and presence of endothelial nitric oxide synthase and cyclooxygenase inhibitors
(L-NAME and indomethacin). The fatty acid composition of cardiac phospholipids was then evaluated.
Results: Although all the HF-fed rats increased their abdominal adiposity, some of them did not gain body weight
(HF- group) compared to the C group whereas other ones had a higher body weight (HF+). All HF rats displayed a
higher in vivo cardiac activity associated with an increased EDV. In the HF- group, the improved EDV was due to an
increase in the endothelial cell vasodilatation activity whereas in the HF+ group, the enhanced EDV resulted from an
improved sensitivity of coronary smooth muscle cells to nitric oxide. Furthermore, in the HF- group the main pathway
implicated in the EDV was the NOS pathway while in the HF+ group the COX pathway.
Conclusions: Nascent obesity-induced improvement of cardiac function may be supported by an enhanced coronary
reserve occurring via different mechanisms. These mechanisms implicate either the endothelial cells activity or the
smooth muscle cells sensitivity depending on the body adiposity of the animals.
Keywords: Obesity, Cardiac function, Coronary reserve, Nitric oxide, Cyclooxygenase, Arachidonic acid
Background
High-fat (HF) diets are now common in the Western so-
cieties and may induce insulin resistance (IR) when the
absorbed lipids are rich in saturated fatty acids (SFAs)
and poor in n-3 polyunsaturated fatty acids (PUFAs) [1].
IR, often associated with hyperglycemia, abdominal
obesity, hypercholesterolemia, hypertriglyceridemia and
hypertension, constitutes one of the major causes of the
metabolic syndrome. This last pathology predisposes pa-
tients to numerous chronic diseases such as type 2 dia-
betes, atherosclerosis, myocardial infarction, stroke and
renal disease [2,3].
Abdominal obesity could be the main catalyst of IR and
associated detrimental events [4] and could have a potent
effect on myocardial function. In the long term, this ab-
normality is known to depress cardiac function and induce
severe cardiomyopathy [5]. The reduced cardiac function
has already been observed in vivo and in vitro in several
animal models of obesity including the Zucker Diabetic
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Fatty rat (ZDF) [6], post-natal over nutrition-related rat
[7,8] and HF-fed rat [9]. However, as exemplified by post-
natal over nutrition-induced obesity, the in vivo ejection
fraction increases firstly until the third month of age and
decreases only after a longer period of obesity [8]. The ini-
tial increase in cardiac output is a normal adaptation de-
signed to compensate for the increased body weight and
related energy expenditures. It could be due to the aug-
mentation of blood and left ventricle telediastolic vol-
umes encountered in those situations [8] which would
contribute to increase myocardial contractility through
the Frank Starling’s relationship. However, that im-
provement is only transitory and could be responsible
for the later cardiomyopathy.
Associated with the improved cardiac output of the early
phase of obesity an increased coronary flow and reserve
could occur. Yet, all studies concerning this last parameter
showed either an upholding [7,10-12] or a depression of
the coronary reserve [13-18]. There is only one study per-
formed on the isolated coronary arteriole [11] mentioning
an obesity-related enhancement of the sensitivity of the
coronary smooth muscle cells (SMCs) to nitric oxide
(NO), which was however not associated with an improved
endothelial-dependent vasodilatation (EDV).
The present study was aimed at evaluating the effects of
the precocious development of obesity induced by a HF
diet on the in vivo cardiac function and the ex vivo coron-
ary reserve and at analyzing the mechanisms by which
these alterations occurred. For that purpose, male Wistar
rats were fed for 3 months with a diet high in saturated
and monounsaturated fatty acids (MUFAs). All HF-fed an-
imals gained abdominal adiposity compared to the control
group, but only some of them gained body weight. This
allowed the estimation of the effects of normal weight
(gain in abdominal obesity, but no gain in body weight)
and moderate (gain in abdominal adiposity and body
weight) obesity on the cardiac mechanical function and
coronary reserve. In order to explain the observed phe-
nomena, the sensitivity to NO of SMCs (endothelial-in-
dependent vasodilatation or EIV) and endothelial cell
vasodilatation activity (ECVA) were determined. The in-
fluence of nitric oxide synthase (NOS) and cyclooxygenase
(COX) inhibitors on the EDV was also estimated. Further-
more, in order to investigate the molecular mechanism of
each effect, the fatty acid composition of cardiac phospho-
lipids was evaluated.
Methods
Ethical approval
All experiments followed the European Union recom-
mendations concerning the care and use of laboratory
animals for experimental and scientific purposes. All ani-
mal work was approved by the local board of ethics for
animal experimentation (Cometh) and notified to the
research animal facility of our laboratory (authorization
n° 152_LBFA-U1055-LD-03).
Experimental animals and diet
Ninety male Wistar rats from an inbred colony were
housed two per cage in our animal facility at 3 months
of age. Forty-five of them were randomly assigned to be
maintained on standard carbohydrate (C) (16.1% pro-
teins, 3.1% lipids, 60% cellulose; A04, Safe, France) diet
and the fifty-one others were fed a high-fat (HF) (31.5%
proteins, 54% lipids (50% lard, 4% soya-bean oil w/w),
7% cellulose) diet over a twelve-week period. The en-
ergy from fat in this diet typically represents more than
50% of total calories [19,20] as in an average Western
diet. After analysis of the fatty acid composition of the
diets chosen we found that the standard diet contained
approximately 24% of SFAs, 23% of MUFAs, 48% of n-6
PUFAs and 4.5% of n-3 PUFAs while the HF diet con-
tained 37% of SFAs, 46% of MUFAs, 15% of n-6 PUFAs
and 1.2% of n-3 PUFAs. All groups were fed ad libitum
with free access to water and their body weight and food
intake were recorded twice weekly. It should be noted
that the protein content of the HF diet was 2-fold
higher because of the lower food intake (g/day) in these
rats due to the higher energy density. This allowed a
similar daily protein intake in all rat groups.
In a first set of experiments, eight rats fed with either
the control or the HF diet were used to determine car-
diac function in the in vivo situation.
In a second series of experiments, six rats were fed
with the control diet and twelve animals with the HF
diet. These animals were used to evaluate the effect of
the diet on the body and blood compositions, ex vivo
cardiac mechanical function and coronary reactivity, ac-
tivities of the respiratory chain complexes and fatty acid
composition of cardiac phospholipids. On the day of the
experiment, the rats were weighed and heparinized
(1,000 I.U./kg) via the saphenous vein before their sacri-
fice. The rats were allowed to eat up to the beginning of
the experiment. Blood samples were collected for fur-
ther biochemical analysis and their visceral (VAT) and
peri-renal (PRAT) adipose tissue was weighed. Abdom-
inal adipose tissue (AAT) weight was the sum of VAT
and PRAT weights.
In a third set of experiments, twenty-four rats were
fed with the control diet and thirty-two with HF one.
The rats of each dietary group were further divided in
four subgroups (n = 6 per group for the control rats and
n = 4 for the HF-fed rats) in order to evaluate the effect
of the diet on the ex vivo coronary reactivity in the ab-
sence of inhibitors, in the presence of L-NAME (a NOS
inhibitor), in the presence of indomethacin (a COX in-
hibitor) and in the presence of both inhibitors.
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Oral glucose tolerance test (OGTT)
An OGTT was performed 2 weeks before the sacrifice.
Food was removed from rats 18 h before they were given
orally a glucose dose (1 g glucose/kg body weight, between
08.00 and 10.00 am). Blood samples were collected from
the tail vein in heparinized tubes immediately before glu-
cose administration to determine the basal glucose and in-
sulin values and 5, 25, 40, 60 and 180 min after. Glucose
values were determined with a glucose analyzer (ACCU-
CHECK Active, Softclix). After centrifugation (3000 × g,
7 min, 4°C) plasma samples were stored at −20°C until
insulin determination using a radioimmunoassay kit
(SRI-13 K, Millipore, Molheim, France). The total area
under the curve (AUC) for glucose was then calculated
in order to evaluate the glucose tolerance as previously
used by Cortez et al. [21].
In vivo cardiac function
After deep anesthesia with sodium pentobarbital (40 mg/kg),
the animal throat was dissected in order to isolate the
right carotid artery. That artery was clamped at the
proximal level in order to stop the blood flow arriving
from the heart and a pressure gauge (Millar Instruments
Inc., Houston, Texas) related to an amplifier (Gould)
was introduced downstream through a small incision in
the vessel. The clamp was removed and the gauge was
progressively introduced in the aorta and then in the left
ventricle cavity. The left ventricle pressure was then moni-
tored after a 10 min-period of stabilization. The heart rate,
systolic, diastolic, developed pressures, dP/dt max and dP/
dt min were determined from the recordings.
Ex vivo cardiac function
For the ex vivo Langendorff assessment of the cardiac func-
tion, a rapid thoracotomy was performed on the rats and
the heart was immediately collected in Krebs-Heinselet so-
lution maintained at 4°C. It was then rapidly (less than 1 -
minute from the chest opening to avoid problem of cellular
damages and preconditioning) perfused at constant
pressure according to the Langendorff mode with a
Krebs–Heinselet buffer containing (in mM) NaCl 119,
MgSO4 1.2, KCl 4.8, NaHCO3 25, KH2PO4 1.2, CaCl2
1.2 and glucose 11 mM as sole energy substrate. The
buffer was maintained at 37°C and continuously oxy-
genated with carbogen (95% O2/5% CO2). A latex bal-
loon connected to a pressure probe was inserted into
the left ventricle and filled until the diastolic pressure
reached a value of 7–8 mmHg. This allowed the moni-
toring of heart rate, systolic, diastolic and left ventricle
developed pressures throughout the perfusion protocol.
A pressure gauge inserted into the perfusion circuit just
upstream the aortic cannula allowed the evaluation of
the coronary pressure. The heart was perfused at con-
stant pressure of 59 mmHg for 30 minutes and the
coronary flow for each heart was evaluated by weight
determination of 1-min collected samples at the 25th
min of perfusion. After this period, the heart was per-
fused at constant flow conditions, for which the flow
rate was adjusted in order to obtain the same coronary
flow as in the preparation at constant pressure. The sys-
tolic, diastolic and left ventricle developed pressures as
well as the heart rates were determined after 10 min of
perfusion at forced flow in order to allow a satisfying
stabilization of the heart. The left ventricle developed
pressure (LVDP) was calculated by substracting the dia-
stolic pressure to the systolic pressure. The rate-pressure
product (RPP) was defined as the product of left ventricle
developed pressure and heart rate. All the parameters
were recorded and analyzed with a computer using the
HSE IsoHeart software (Hugo Sachs Elektronik, March-
Hugstetten, Germany).
Ex vivo coronary reactivity
After the evaluation of the cardiac function at constant
flow, we assessed the effects of the HF diet on the cor-
onary reactivity. After the 10-min equilibration period at
constant flow, the coronary tone was raised by using the
thromboxane analog U46619 (30nM), which was con-
stantly infused into the perfusion system near the aortic
cannula at a rate never exceeding 1.5% of the coronary
flow. This allowed the obtainment of a coronary pres-
sure between 90 and 110 mmHg. In our model of perfu-
sion at forced flow, the aortic pressure equaled the
coronary pressure and changes in the coronary tone trig-
gered modifications of the aortic pressure. Changes in
aortic perfusion pressure were thus used to monitor
changes in coronary tone. Furthermore, this experimen-
tal model permitted the evaluation of the coronary mi-
crovasculature reactivity since in the rat the overall
coronary pressure is determined mainly by the coronary
resistance vessels. Relaxation responses to acetylcholine
(Ach, 4, 10, 20, 40, 60, 80 and 100 pmoles) and sodium
nitroprusside (SNP, 100, 200, 400, 600, 800 and 1000
pmoles) injections were determined reflecting the EDV
and EIV respectively.
The choice of these ACh doses was made in order to
avoid the ACh-induced negative inotropic effect, which
decreases the EDV. This dose was never reached in our
study, since the cardiac mechanical function was never
impaired by the ACh injection. From the obtained dose re-
sponse curves, it is obvious that the ACh-induced vaso-
dilatation was saturated for the highest tested doses.
Consequently, the maximal ACh-induced vasodilation was
reached and the coronary reserve measured amongst the
ACh doses used in our study.
The dilatation amplitude was calculated as the ratio be-
tween the maximal decrease in the coronary pressure and
the coronary pressure just before the injection of the
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dilatation agents. Since the heart weight and coronary vol-
ume were subjected to intra- and inter-group variations, a
correction was performed to normalise the input-function
of the vasodilatation agents according to the coronary
flow. The dose–response curve between the amount of
vasodilatation agent injected and the maximal vasodilata-
tion was then fitted to a logarithm function for each
heart, which allowed the fulfillment of statistical ana-
lyses. Moreover, the vasodilatation activity of the endo-
thelial cells (ECs) was also estimated from the corrected
EDV and EIV curves. For each heart and each injected
ACh dose, the amount of SNP (reflecting the amount of
vasodilator agents) necessary to obtain the same per-
centage of ACh-induced vasodilatation was extracted
from the EIV curve according to the formula: ECVA = e
[(% ACh-induced dilatation - b) / a], where a and b are the coef-
ficients of the theoretical EIV curve. The results were
expressed in pmole equivalents of nitroprusside. At the
end of the perfusion protocol, the hearts were freeze-
clamped and stored at −80°C until the biochemical ana-
lyses were performed.
In another set of coronary reactivity experiments, the
hearts of the control and HF groups were perfused as
already described and the EDV was evaluated in presence
of a NOS inhibitor (L-NAME 0.1 mM) or a COX inhibitor
(indomethacin 2.5 μM). Finally, hearts were perfused in
the simultaneous presence of L-NAME (0.1 mM) and
indomethacin (2.5 μM).
Enzymatic determinations
Activities of the respiratory chain complexes I, II, III and
IV were determined as previously described [22]. Citrate
synthase activity was evaluated according to Faloona and
Sreere [23].
Fatty acid composition of cardiac phospholipids
The phospholipid fatty acid composition was determined
in cardiac homogenates as previously described [24]. The
lipids were extracted according to Folch et al. [25]. The
phospholipids were separated from non-phosphorus lipids
using a Sep-pack cartridge [26]. After trans methylation,
the fatty acid methyl esters were separated and analyzed
by gas chromatography.
Other biochemical determinations
All biochemical measurements (total cholesterol, triglycer-
ides, glucose) were done in plasma samples by using an
automated analyzer (HITACHI 912, Roche Diagnostics).
Chemicals were obtained from Roche (Meylan, France).
Proteins were measured using the bicinchoninic acid
method with a commercially available kit (Thermo Scien-
tific, Rockford, IL).
Statistical analysis
Results are presented as mean ± S.E.M. Animal weight,
metabolic parameters and data describing the cardiac
mechanical and vascular function (left ventricular devel-
oped pressure, heart rate, rate pressure product, coronary
pressure, and coronary flow) were contrasted across the
two groups by one-way analysis of variance (ANOVA).
Measures related to the action of the vasodilatation agents
were treated with repeated-measures ANOVA to test the
effect of the group (external factor), that of the amount of
dilatation agent (internal factor) and their interactions.
When required, group means were contrasted with a
Fisher’s LSD test. A probability (p) less than 0.05 was
considered significant. Statistical analysis was per-
formed using the NCSS 2007 software.
Results
General data
During the experiments, analysis of the animal weight
indicated that six rats of the HF-fed group did not gain
weight compared to the control group during the 3-
month dietary period, whereas the six others became
significantly heavier than those of the control group.
This delineated three distinct groups: i) the control (C)
rats fed the control diet; ii) the animals whose weight
did not differ from the control animals despite ingestion
of the dense food (HF- group); and iii) the animals that
gained weight due to the HF diet (HF+ group). However,
the HF diet increased the adiposity of both HF rat
groups. Table 1 shows statistical analyses indicating that
the HF- group displayed a similar body weight as the C
group and the HF+ group a higher body weight than the
other two ones (+22 and +24% compared to the C and
HF- groups, respectively, p < 0.05). The weight gain after
this 3-month diet period was similar for the C and HF-
groups (+21%) while it was significantly higher in the
HF+ group (+24%). The cumulative dietary intake in the
HF groups was 586 ± 15 and 644 ± 11 g/50 days/rat for
the HF- and HF + groups respectively. The weight ra-
tio between the PRAT and VAT was increased in the
HF- group (2.0 ± 0.4 vs. 0.8 ± 0.1 in the C group, +150%,
p < 0.05), but was intermediary in the HF + group (1.3 ± 0.4,
not significant). Consequently, in the HF- rats, fat mass lo-
calized more in the peri-renal area and less in the visceral
area compared to the HF + animals. The heart weight
was decreased by the HF diet. However, that reduction
was significant in those animals remaining lean (−18%
for the HF- group, p < 0.05), but a tendency remained
in the HF+ group.
There were no statistically significant differences be-
tween the groups regarding the values of blood glucose
and insulin on the day of sacrifice. However, the total
area under the curve for glucose was moderately in-
creased in the HF- group whereas it was significantly
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increased in the HF+ group (+18%, p < 0.05) compared
to the control one. Total cholesterol concentrations were
higher in the HF-fed rats (+72 and +58% for the HF-
and HF+ compared to the control animals, p < 0.05).
This was also the case for the triglyceride concentration
in the HF- group (+66%, p < 0.05), but not in the HF+
group in which the difference did not reach significance
(+28% only, not significant).
In vivo cardiac function
Table 2 depicts the in vivo cardiac function in the HF
diet-fed rats. The heart rate was not significantly af-
fected by the diet. Conversely, the systolic pressure,
LVDP, dP/dt max and dP/dt min were increased in the
HF- group (+28, +33, +38% and + 36% compared to the
C group respectively, p < 0.05), suggesting an augmented
contractile function. These parameters were also moder-
ately increased in the HF+ group (+17, +19, +24% and +
22% compared to the C group respectively, not significant).
Ex vivo cardiac function
The heart rate was not affected by the diet (Table 3), but
the LVDP was decreased in the HF+ group (−32% com-
pared to the C group, p < 0.05). However, the reduction of
LVDP was not significant in the HF- group. The RPP was
always reduced by the HF diet irrespective of the body
weight change of the animals (−27 and −28% for HF- and
HF+ groups compared to the C group, p < 0.05). The de-
creased mechanical function occurred despite maintained
coronary flows and pressures. Infusing the vasoconstrictor
agent U46619 increased the coronary pressure to values
ranging from 94 to 120 mmHg, but did not modify the
rate pressure product (data not shown).
Ex vivo coronary reactivity: effect of body weight change
The Figure 1A demonstrating the ACh-induced vasodilata-
tion clearly indicates that the HF-diet increased that param-
eter. This was true for the HF- group (+36% when the
administrated ACh dose was 60 pmoles, p < 0.05), but also
for the HF+ group (+48% at 60 pmoles of administrated
ACh, p < 0.05). As indicated by Figure 1B and 1C, the HF
diet-induced increase in EDV did not originate from the
same mechanism in the two HF-fed rat groups. When the
HF-fed animals did not gain weight (HF- group), the in-
crease in ACh-induced vasodilatation was due to an aug-
mentation of the ECVA (Figure 1C). Indeed, the ECVA was
increased in that group (i.e. +53% at 60 pmoles of adminis-
trated ACh, p < 0.05), whereas in the HF + group it dis-
played similar values as in the C group. On the contrary,
when the HF-fed animals gained weight (HF + group), the
increase in EDV was mainly due to an augmentation of the
SNP-induced vasodilatation (Figure 1B), outlining the es-
sential role of SMCs relaxation. In that last group, the EIV
Table 1 Animal characteristics
C HF- HF+
Final body weight 438 ± 7a 429 ± 10a 534 ± 8b
Body weight gain 90 ± 3a 88 ± 4a 129 ± 6b
Heart weight 57 ± 2a 47 ± 3b 48 ± 6a,b
PRAT 1.2 ± 0.1a 3.6 ± 0.7b 3.2 ± 0.7b
VAT 1.5 ± 0.2a 1.9 ± 0.2a,b 2.5 ± 0.3b
AAT 2.7 ± 0.3a 5.4 ± 0.7b 5.8 ± 0.9b
Glucose 5.06 ± 0.34 5.17 ± 0.17 5.31 ± 0.05
Insulin 153 ± 17 106 ± 13 145 ± 26
Triglycerides 0.97 ± 0.06a 1.61 ± 0.25b 1.24 ± 0.04a,b
Total cholesterol 0.53 ± 0.01a 0.91 ± 0.07b 0.84 ± 0.06b
Total AUCglucose 29077 ± 1048a 32298 ± 1167a,b 34364 ± 2060b
The number of experiments was 6 per group. The body weight and body
weight gain was expressed in g, the heart weight in mg of dry weight per
100 g of body weight, the weight of the perirenal (PRAT), visceral (VAT) and
abdominal (AAT) adipose tissues in g of wet weight per 100 g of body weight,
the concentration of glucose in mM, the concentrations of triglycerides and
total cholesterol in g/l, the insulin concentration in mU/l and the total area
under the curve (AUCglucose) in arbitrary units. C: control group; HF-: high
fat-fed animals without weight gain compared to the control rats; HF+: high
fat-fed animals with weight gain compared to the control rats; a, b: two means
located on a same line without a common letter are significantly different.
Table 2 In vivo cardiac function
C HF- HF+
HR 347 ± 20 397 ± 9 370 ± 24
SP 128 ± 4a 164 ± 14b 150 ± 14a,b
DP 21 ± 1 20 ± 1 21 ± 1
LVDP 108 ± 4a 144 ± 14b 129 ± 14a,b
dP/dt max 3350 ± 206a 4608 ± 530b 4163 ± 531a,b
dP/dt min −3275 ± 180a −4467 ± 457b −3981 ± 513a,b
The number of experiments was 8, 4 and 4 for the C, HF- and HF + groups.
The heart rate, pressures (systolic, diastolic and left ventricular developed
pressures), dP/dt max and dP/dt min were expressed in beats/min, mmHg and
mmHg/s. C: control; HF-: high fat-fed rats without weight gain; HF+: high
fat-fed rats with weight gain; HR: heart rate; SP: systolic pressure; DP: diastolic
pressure; LVDP: left ventricular developed pressure; dP/dt max: maximum rate of
pressure change; dP/dt min: maximum rate of pressure change; a, b: two means
located on a same line without a common letter are significantly different.
Table 3 Ex vivo cardiac function
C HF- HF+
Heart rate 288 ± 29 248 ± 20 295 ± 20
LVDP 82 ± 10a 67 ± 2a,b 56 ± 7b
RPP 22.9 ± 1.5a 16.8 ± 1.7b 16.4 ± 1.7b
Coronary flow 42.9 ± 7.5 40.2 ± 6.7 42.9 ± 13.7
CP before U46619 62.8 ± 6.4 67.5 ± 5.9 68.4 ± 3.8
CP after U46619 94.0 ± 3.9 106.0 ± 8.5 120.4 ± 7.7
The number of experiments was 6 per group. The heart rate, pressures
(left ventricular developed pressure or LVDP, coronary pressure or CP before
and after U46619 infusion), rate pressure product (RPP) and coronary flow
were expressed in beats/min, mmHg, mHg/min and ml/min/g of dry weight.
C: control group; HF-: high fat-fed animal without weight gain compared to
the control group; HF+: high fat-fed animals with weight gain compared to
the control group; a, b: two means located on a same line without a common
letter are significantly different.
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was increased by 39% at the administrated SNP dose of
600 pmoles compared to the C group (p < 0.05), whereas
it remained similar to the one of the C group in the HF-
animals.
Ex vivo coronary reactivity: effects of NOS and
cyclooxygenase inhibitors
The high coronary pressure induced by the U46619 infu-
sion allowed the determination of the effects of the vasodi-
lators ACh and SNP. The effects of each inhibitor were
also calculated at 60 pm of the Ach injected dose.
In the absence of inhibitor, the EDV was increased by
the HF diet (i.e. +41% compared to the C group at the
dose of 60 pmoles, p < 0.05, Figure 2). The presence of
L-NAME reduced the EDV significantly only in the HF-
group (−71% at 60 pmoles of injected ACh, p < 0.05)
whereas indomethacin reduced this parameter only in
the HF + group (−43% at 60 pmoles of injected ACh, p <
0.05). The presence of both inhibitors in the perfusate
significantly reduced the EDV in both HF groups (−58%
and −38% for the HF- and HF + groups respectively at
60 pmoles of injected ACh, p < 0.05).
Respiratory chain complexes activities
Citrate synthase activity (Table 4) was of similar magni-
tude in the three groups. It was also true for C1 and C4
activities. C2 activity was decreased by the HF diet irre-
spective of the animal body weight change (−15% for the
HF- and HF + groups compared to the C group when the
values were expressed in unit per unit of citrate synthase,
p < 0.05). That slight difference was however erased when
the values were normalized to the amount of cardiac pro-
teins. Finally, C3 activity appeared the most affected by
the dietary intervention. That parameter was reduced by
the HF diet when the animals did not gain weight (−26
and −28% for the values expressed in relation to the
amount of mitochondria and the amount of myocardial
proteins, p < 0.05), but was similar to the C group value
for the HF+ group.
Fatty acid composition of cardiac phospholipids
The fatty acid composition of myocardial phospholipids is
presented in Table 5. SFAs were increased by the HF diet
(+12 and +11% in the HF- and HF+ groups, p < 0.05) at
Figure 1 Effects of the diets on the reactivity of the coronary
microvasculature. (A) Endothelial-dependent vasodilatation (EDV).
(B) Endothelial-independent vasodilatation (EIV). (C) Endothelial cell
vasodilatation activity (ECVA). C: control; HF- : HF-fed rats with no
body weight change; HF+: HF-fed rats with body weight gain; Ach:
acetylcholine; SNP: sodium nitroprusside. The number of experiments
was 6 per group. a, b: significantly different.
Figure 2 Effects of HF diet, L-NAME and Indomethacin on the
EDV of the coronary microvasculature at 60 pm of injected Ach
dose. The number of experiments was 6 for the control groups and
4 for the HF groups. C: control animals; HF-: HF-fed rats with no
body weight change; HF+: HF-fed rats with body weight gain; Ach:
acetylcholine. a, b: values without a common letter are significantly
different; *: significant difference in the HF- group in the absence or
presence of inhibitors; #: significant difference in the HF+ group in
the absence or presence of inhibitors.
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the expense of the MUFAs (−20 and −26%, p < 0.05).
However, the proportions of total PUFAs, n-6 PUFAs and
n-3 PUFAs were not altered.
Some alterations occurred inside the lipid classes. The
SFAs DMA C18:0, C18:0 and C22:0 were increased by the
HF diet (+132, +25 and +63% compared to the C group,
p < 0.05). Interestingly, the proportion of C18:0 was more
increased in the HF- group (+29%, p < 0.05) than in the
HF+ group (+22%, p < 0.05). In the MUFAs, the propor-
tions of C18:1 n-9 was amplified by the HF diet at the det-
riment of the n-7 fatty acids (−76 and −47% for the C16:1
n-7 and C18:1 n-7, p < 0.05). In the n-6 PUFAs, the pro-
portion of C18:2 n-6 was drastically decreased by the HF
diet, but that reduction was ampler in the HF- group
(−30%, p < 0.05) than in the HF+ group (−14%, p < 0.05).
Except for the C18:3 n-6 which was also reduced, all the
other n-6 PUFAs (C20:2 n-6, C20:3 n-6, C20:4 n-6, C22:4
n-6 and C22:5 n-6) were increased by the HF diet in a
similar way for both HF- and HF + groups. The only ex-
ception was the C20:4 n-6, which was highly augmented
in the HF- group (+23%, p < 0.05) and only moderately in
the HF+ group (+11%, not significant). The HF diet-
induced tendency to augment the carbon chain length of
the membrane PUFAs was also true for the n-3 PUFAs.
Indeed, the HF diet increased the proportion of C22:5 n-3
(+143 and +141% for the HF- and HF+ groups, p < 0.05).
As indicated by the C18:0/C16:0, C18:1 n-7/C16:1 n-7,
C20:2 n-6/C18:2 n-6, C22:4 n-6/C20:4 n-6 and C22:5 n-
3/C20:5 n-3 ratios, activities of the elongases were in-
creased by the HF diet. Conversely, activities of the Δ9-,
Δ6- and Δ5-desaturases were reduced as suggested by
the reduction of the C16:1 n-7/C16:0, C18:3 n-6/C18:2
n-6 and C20:4 n-6/C20:3 n-6 ratios. Finally, the n-6 to
Table 4 Activities of the respiratory chain complexes in
myocardial biopsies
Enzyme C HF- HF+
CS mU./mg 4.3 ± 0.1 4.4 ± 0.2 4.6 ± 0.4
C1 U./U. CS 0.24 ± 0.01 0.20 ± 0.02 0.21 ± 0.03
mU./mg 1.05 ± 0.05 0.82 ± 0.07 0.99 ± 0.22
C2 U./U. CS 0.20 ± 0.01a 0.17 ± 0.01b 0.17 ± 0.01b
mU./mg 0.85 ± 0.03 0.78 ± 0.05 0.79 ± 0.08
C3 U./U. CS 0.068 ± 0.004a 0.050 ± 0.005b 0.064 ± 0.002a
mU./mg 0.29 ± 0.01a 0.21 ± 0.02b 0.29 ± 0.03a
C4 U./U. CS 0.024 ± 0.001 0.020 ± 0.002 0.020 ± 0.002
mU./mg 0.101 ± 0.006 0.079 ± 0.006 0.094 ± 0.013
The number of experiments was 6 per group. Citrate synthase (CS) activities
were expressed in mU./mg of myocardial proteins. Complex 1, 2, 3 and 4 (C1,
C2, C3, C4) activities were expressed either in mU./mg of myocardial proteins
(mU./mg) or in units/unit of citrate synthase activity (U./U. CS). C: control
group; HF-: high fat-fed animals without weight gain compared to the control
group; HF+: high fat-fed animals with weight gain compared to the control
group; a, b: two means located on a same line without a common letter are
significantly different.
Table 5 Fatty acid composition of cardiac phospholipids
Fatty acid C HF- HF+
C14:0 0.06 ± 0.01 0.08 ± 0.01 0.08 ± 0.01
DMA C16:0 3.22 ± 0.17 3.04 ± 0.17 3.34 ± 0.19
C16:0 13.15 ± 0.14 10.30 ± 0.48 11.38 ± 1.15
DMA C18:0 1.07 ± 0.05a 2.49 ± 0.12b 2.47 ± 0.20b
C18:0 21.27 ± 0.09a 27.42 ± 0.26b 25.86 ± 0.71c
C22:0 0.04 ± 0.01a 0.06 ± 0.01b 0.07 ± 0.01b
C24:0 0.15 ± 0.01a 0.06 ± 0.01b 0.05 ± 0.01b
SFA 38.82 ± 0.25a 43.44 ± 0.85b 43.24 ± 1.81b
C16:1 n-7 0.51 ± 0.05a 0.12 ± 0.01b 0.12 ± 0.05b
C16:1 n-9 nd 0.05 ± 0.03 0.07 ± 0.02
C18:1 n-7 5.24 ± 0.19a 2.91 ± 0.05b 2.60 ± 0.35b
C18:1 n-9 3.24 ± 0.04a 4.02 ± 0.07b 3.72 ± 0.27a,b
C20:1 n-9 0.07 ± 0.01 0.07 ± 0.01 0.07 ± 0.01
MUFA 8.91 ± 0.24a 7.17 ± 0.09b 6.57 ± 0.51b
C18:2 n-6 26.49 ± 1.27a 18.65 ± 0.49b 22.82 ± 1.08c
C18:3 n-6 0.02 ± 0.01a 0.01 ± 0.01b 0.01 ± 0.01b
C20:2 n-6 0.10 ± 0.01a 0.22 ± 0.01b 0.21 ± 0.02b
C20:3 n-6 0.28 ± 0.02a 0.59 ± 0.03b 0.64 ± 0.06b
C20:4 n-6 17.02 ± 0.34a 20.95 ± 0.84b 18.89 ± 1.10a,b
C22:4 n-6 0.24 ± 0.01a 0.50 ± 0.04b 0.46 ± 0.05b
C22:5 n-6 0.21 ± 0.03a 0.52 ± 0.03b 0.43 ± 0.05b
n-6 PUFA 44.36 ± 1.05 41.42 ± 0.48 43.45 ± 1.02
C18:3 n-3 0.02 ± 0.01 0.04 ± 0.01 0.05 ± 0.02
C20:5 n-3 0.12 ± 0.01 0.12 ± 0.03 0.09 ± 0.04
C22:5 n-3 0.75 ± 0.09a 1.82 ± 0.14b 1.81 ± 0.23b
C22:6 n-3 5.54 ± 0.22 6.00 ± 0.44 4.78 ± 0.46
n-3 PUFA 6.37 ± 0.21 7.98 ± 0.58 6.73 ± 0.67
Total PUFA 52.43 ± 0.12 49.40 ± 0.86 50.18 ± 1.55
n-6/n-3 7.00 ± 0.10a 5.28 ± 0.38b 6.62 ± 0.57a
EPA/AA 0.0068 ± 0.0008 0.0056 ± 0.0012 0.0043 ± 0.0019
EPA + DHA 5.66 ± 0.21 6.12 ± 0.44 4.87 ± 0.50
C18:0/C16:0 1.62 ± 0.02a 2.68 ± 0.11b 2.33 ± 0.18b
C18:1 n-7/C16:1 n-7 10.9 ± 1.6a 24.8 ± 0.9b 18.1 ± 5.6a,b
C20:2 n-6/C18:2 n-6 3.9 ± 0.1a 11.6 ± 0.8b 9.0 ± 0.7c
C22:4 n-6/C20:4 n-6 1.4 ± 0.1a 2.4 ± 0.2b 2.4 ± 0.1b
C22:5 n-3/C20:5 n-3 7.2 ± 1.7a 18.1 ± 5.2a,b 32.6 ± 9.3b
C16:1 n-7/C16:0 4.0 ± 0.6a 1.1 ± 0.1b 1.0 ± 0.3b
C18:3 n-6/C18:2 n-6 7.8 ± 0.5a 4.1 ± 1.4b 3.4 ± 1.1b
C20:4 n-6/C20:3 n-6 62.7 ± 5.6a 36.1 ± 2.8b 30.8 ± 4.7b
The number of experiments was 6 per group. Except for the different ratios, the
results are expressed in percent of total fatty acids. The C22:4 n-6/C20:4
n-6 and C16:1 n-7/C16:0 ratios must be multiplied by 10−2. The C20:2 n-6/C18:2 n-6
and C18:3 n-6/C18:2 n-6 ratios must be multiplied by 10−3 and 10−4, respectively.
DMA: dimethylacetal; SFA: saturated fatty acids; MUFA: monounsaturated fatty acids;
PUFA: polyunsaturated fatty acids; EPA: eicosapentaenoic acid; AA: arachidonic acid;
DHA: docosahexaenoic acid. C: control group; HF-: high fat-fed animals without
weight gain compared to the control rats; HF+: high fat-fed animals with weight
gain compared to the control rats; a, b, c: two means located on a same line without
a common letter are significantly different.
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n-3 PUFA ratio of cardiac phospholipids was decreased in
the HF- group (−25%, p < 0.05), but not in the HF+ group.
Discussion
The present study was aimed at determining the effects
of a 3-month HF diet rich in SFAs and MUFAs on the
cardiac function and at investigating the underlying
mechanism at the level of coronary circulation. Despite
its high percentage in fat content, the high-fat diet
chosen for this study did not induce severe obesity in
the animals but increased significantly their adiposity,
which was accompanied or not by body weight gain. The
increased adiposity of the animals was related to changes
observed in the in vivo and ex vivo cardiac function as
well as in the ex vivo coronary reactivity. However, the
body weight change and thus the adipose tissue distribu-
tion seemed to affect the mechanism through which the
changes at the coronary level occurred.
Feeding rats for 3 months with a HF diet containing
large amounts of SFAs and MUFAs was expected to gen-
erally increase the body weight of the animals. During
the experiments two distinct groups were observed in
the HF-fed animals with one of them being character-
ized by no body weight change compared to the control
group (HF-) and the other showing an increased body
weight (HF+). These two groups displayed a similar in-
crease in abdominal adiposity and were thus clearly dif-
ferent from the C group. The HF + group was composed
of obese animals, since their body weight and abdominal
adiposity were increased. However, the body weight was
moderately increased compared to the C group. These
animals were thus considered as moderately obese. The
HF- rats were not distinctly obese, since they had an in-
creased abdominal adiposity but no augmentation of
body weight. As the case with high body weight and ab-
dominal adiposity can occur in humans, the situation
with low body weight and high abdominal adiposity also
exists and refers to abnormal and hazardous body com-
position with high risk of chronic pathological events
[27]. Indeed, this situation is interesting to study since it
has been recently recognized in the literature the exist-
ence of different subtypes of obesity such as metabolic-
ally healthy but obese (elevated body fat but normal
metabolic profiles) and metabolically obese, normal
weight individuals that may be or not at increased car-
diovascular risk. Furthermore, a new syndrome has been
described lately in humans, the normal weight obesity
syndrome, which is defined as a normal body mass index
associated with increased body fat [28]. Thus, the study
of these two HF subgroups allowed the study of two dif-
ferent subtypes of obesity that correspond to different
situations of obesity occurring in humans.
The fact that the fat content of the HF diet chosen
was not consisted entirely by saturated fat or that the
protein content was doubled in our HF diet might ex-
plain the state of obesity that we found in our rats. It
could also explain any differences concerning basic char-
acteristics of the animals from previous studies, such as
body weight and glucose levels [11,29]. Futhermore,
Buettner et al. have shown that PUFA- or medium-chain
fatty acids-rich diets did not induce insulin resistance in
rats after a 12 week period [30]. Indeed, in the HF diet
chosen for this study one can find not only SFA but also
a percentage of PUFAs that could explain the metabolic
results of the rats. This diet affected only the triglycer-
ides and cholesterol levels of the rats indicating the be-
ginning of a dyslipidemia. Furthermore, it provoked the
development of glucose intolerance in the HF+ rats,
which is consistent with previous studies [31]. Thus, the
high-fat diet altered the metabolic profile of the HF-fed
rats according to the percentage of the adiposity in their
bodies with the HF- rats having a less obese profile com-
pared to the HF+ rats.
The reason why the HF- animals did not gain body
weight is not known, since we did not evaluate the food
intake and the energy expenditure in our study. For that
reason, we analyzed a previous study in which we deter-
mined the food intake. In that last study, the C diet was
given to five rats and the HF diet to ten rats for a period
of 50 days. As in the present study, the HF diet-fed ani-
mals were divided into two groups of equal sample size
(n = 5) with the lightest and heaviest animals. The ani-
mal weight at the beginning of the experiment was simi-
lar in the three groups (321 ± 3, 318 ± 6 and 316 ± 3 g
for the C, HF- and HF + groups, not significant). At the
end of the fifty day-diet, the animal weight was signifi-
cantly higher in the HF + group (445 ± 8 g) compared to
the two other groups (411 ± 5 and 406 ± 8 g for the C
and HF- groups, respectively). This perfectly fits with
the results of the present study indicating that the HF-
fed rats can either take weight compared to the control
group or not. Indeed, the weight gain of the animals
during the 3 month-feeding period was higher in the
HF+ group compared to the two other ones. Interest-
ingly, the weight gain paralleled that of the cumulative
dietary intake in the HF groups, suggesting that the dif-
ference in weight gain was due to a difference in food in-
take. The palatability of the HF diet could thus be
responsible for the observed differences. It could be high
enough for the subgroup of rats becoming obese and in-
sufficient for the other ones. However, the reduction of
the n-6 to n-3 PUFA ratio of cardiac phospholipids ob-
served in the HF- group could also limit the food intake.
In the present study, despite the different body weight
gains, the abdominal fat mass was of similar magnitude
in the two subgroups of HF diet-fed rats, suggesting that
the excessive caloric intake observed in the HF+ group
was used to build up other tissues in the body. Another
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explanation for the lack of body weight gain in the HF-
group could be an insufficient intake of proteins and a
low lean mass build-up [32-35]. In the present study, the
protein content of the HF diet was planned to be twice
as high as that of the C diet in order to compensate for
the lower food intake due to the dietary lipid enrich-
ment. This could be not enough for certain animals in
order to build up a sufficient amount of muscle proteins.
Moreover, a reduced respiratory chain complex 3 activity
which paralleled the decreased n-6 to n-3 PUFA ratio of
membrane phospholipids was observed in the hearts of
the HF- animals. This could lead to a lower rate of ATP
production. If the energy available for biochemical syn-
thesis was also reduced in the skeletal muscle, this could
lead to decreased protein build-up and muscle mass for-
mation. The phenomenon would not occur in the HF+
group, since the respiratory chain complex 3 activity and
n-6 to n-3 PUFA ratio of membrane phospholipids were
as high as in the C group. However, the formation of
these two HF subgroups reveals that a HF diet can have
differential effects on the body and blood composition of
the individual.
The HF diet chosen for this study triggered an in-
crease in the in vivo contractile function of the animals
especially that of the HF- rats, whereas the HF+ rats had
an intermediate profile between control and HF- rats.
However, these results were not found in the ex vivo
situation. Indeed, the ex vivo cardiac mechanical func-
tion was reduced by the HF diet, following the elevated
adiposity of the animals irrespective of their body
weight. That observation has already been presented in
the literature after a HF diet period [9,31], after weight
gain through post-natal overfeeding in the mouse [7]
and in the rat [8] as well as in the ZDF rat [6]. This de-
pressed ex vivo cardiac mechanical activity observed in
this study could be related to changes in the cardiac
metabolism related to the whole body glucose intoler-
ance, the increased degree of saturation of the cardiac
membranes as shown by the increase in the SFAs at the
detriment of MUFAs [36] and the pro-inflammatory en-
vironment as indicated by the low ratio EPA/AA that
predisposes to a balance of eicosanoids favoring plate-
let aggregation and inflammatory signaling [37,38].
However, an increased cardiac output is expected to
occur with nascent low- and moderate-severity obesity
[8]. Indeed, our in vivo cardiac function measurements
suggest an augmented inotropism after the 3-month
HF diet intake as already shown by measurements of
the in vivo ejection fraction after post-natal overfeed-
ing. That parameter is firstly increased at the age of
3 months before being reduced from the age of
5 months [8]. Thus, nascent obesity may lead to an in-
creased cardiac output resulting from an increased car-
diac mechanical function.
The further study of these two subgroups revealed the
same profile of the ex vivo cardiac and coronary function
after the HF diet but the results were related to different
mechanisms at the level of coronary vessels depending
on the body composition of the animals. These results
indicate that the high-fat diet has an important effect on
the adiposity of the individual, but not necessarily on the
body weight, and that these changes in the adiposity are
related to changes occurring at the level of cardiovascu-
lar function.
We then evaluated the ex vivo coronary reactivity of
the animals according to Langendorff mode. We evalu-
ated the global cardiac reactivity through estimation of
changes in the aortic pressure, which in our model of
Langendorff perfusion at fixed flow reflected mainly the
pressure of the coronary micro vessels. The conductance
vessels may also contribute to the aortic pressure, but no
spasm and no atheroma plaque was expected to occur in
our experimental conditions. This study reports for the
first time that a 3 month HF diet triggered an increase
in EDV of the coronary microvasculature. HF diet- or
post-natal overfeeding-induced obesity has been associ-
ated with either a reduced [14-16,18] or a maintained
[7,10,12] EDV of the coronary vessels. It has also been
reported that glucose intolerance due to high-fat feeding
does not alter myocardial perfusion during hyperemia
[31]. However, Jerebolvszki et al. [11] reported a HF
diet-induced increase in the sensitivity of pressurized
coronary arterioles to NO, suggesting that the coronary
reactivity can be increased in certain circumstances. This
increase in the EDV of the HF-fed animals could aug-
ment the coronary reserve explaining the results of the
in vivo situation.
The HF diet-induced inotropic effect that encountered
in vivo in our experiments fits perfectly with the in-
creased coronary reserve reported ex vivo. This mechan-
ism could also explain results from previous studies
reporting maintenance of myocardial perfusion or pre-
served contractile function after high-fat feeding
[31,39,40]. Hence, early obesity triggers an in vivo in-
crease in contractile function which is supported by an
augmentation of the coronary reserve. The discrepancies
between the ex vivo and in vivo situations observed in
our study could be due to an increased left end diastolic
volume reported to occur in overfed rats [8], which
would stimulate the cardiac contractile function through
the Frank Starling’s law in the in vivo situation.
The augmented EDV observed in our study paralleled
the increase in abdominal fat mass, but was not related
to an augmentation of body weight. It is possible that
the increased fat mass at the abdominal level or at the
pericardiac level if it also occurred acted on the coronary
vessels through a change in adipocytokine release. Sys-
temic leptin is increased with augmented adiposity [41]
Mourmoura et al. Cardiovascular Diabetology 2014, 13:54 Page 9 of 12
http://www.cardiab.com/content/13/1/54
while adiponectin is reduced [42]. The resulting in vivo
adiposity-related changes in coronary function could be
retained ex vivo and contribute to the adaptation of myo-
cardial function in nascent obesity. Indeed, it has been
shown that obesity necessitates higher cardiac mechanical
activity [43-45] due to augmented whole body energy ex-
penditure. As already indicated, in our model of cardiac
perfusion, we measured mainly the reactivity of the coron-
ary microvasculature which determines myocardial perfu-
sion. The increased coronary EDV observed in our study
could reflect an augmented in vivo coronary perfusion due
to an obesity-related increase in cardiac output.
Previous studies suggest that obesity may reduce NO
levels mostly through increased oxidative stress [46] and
that when NO bioavailability is reduced a compensatory
mechanism takes place in order to maintain a normal
coronary function [47]. Adaptation of coronary vessels is
particularly important, as in the coronary circulation
oxygen extraction is near maximal and any mismatch
between blood supply and metabolic demand would de-
teriorate myocardial contractile function [48]. Further-
more, the increase in body mass, either muscular or
adipose, requires higher cardiac output and expanded
intravascular volume to meet the elevated metabolic re-
quirements [45]. Thus, the vascular alterations observed
in our study could help the coronary microvasculature
to adjust the organ perfusion during physiological pro-
cesses such as exercise. Otherwise the heart would not
be able to respond to increased metabolic demands and
lead eventually to ischemic incidents.
In order to evaluate the contribution of the main vaso-
dilator pathways in the observed EDV, inhibitors that
block NO production and COX were used during the
perfusion protocol. The main results were the following:
i) L-NAME reduced EDV in the HF- group, indicating
the implication of NOS pathway in the enhanced ACh
response in the HF group; ii) indomethacin decreased
EDV in the HF+ group, implying an altered balance be-
tween COX-derived vasodilators and vasoconstrictors in
the HF group. The HF diet seems to reduce the avail-
ability of vasoconstrictor mediators and maintain or
even enhance that of vasodilators contributing eventu-
ally to the enhanced EDV. The analysis of the fatty acid
content of the cardiac phospholipids also revealed that
the arachidonic acid (AA, C20:4n-6) was increased in
the HF- rat hearts which could lead eventually to an in-
crease in the COX-vasoactive agents [49]; iii) association
of L-NAME and indomethacin decreased the EDV in
both HF- and HF+ groups. Thus, both NOS and COX
pathways seem to be implicated in the HF-induced ACh
response.
The study of the two HF subgroups (HF-, HF+) during
the last set of experiments helped to elucidate the in-
volvement of the NOS and COX pathways in the
increased ACh-response of the HF rats. The augmented
ACh- response of the HF- rats was due to an increase in
the activity of endothelial cells, as shown by the ECVA
diagram while that of the HF+ rats was due to an in-
creased sensitivity of the smooth muscle cells to NO, as
shown by the response to SNP injections. The mechan-
ism explaining the increased EDV observed in the HF+
rats has already been described in the literature [11] and
was explained by an increased sensitivity to NO of the
SMC guanylate cyclase with consequent augmented cyc-
lic guanosine monophosphate (cGMP) production and
SMC relaxation. This fits well our results since L-NAME
did not affect the EDV of the HF+ rats, indicating that
NOS pathway was not affected, but since SMCs are
more sensitive to NO which leads finally to increased
EDV. Furthermore, the implication of COX-derived va-
sodilators seem to participate in the increased EDV of
the HF+ rats as shown by the results of the indometh-
acin experiments. However, more original was the mech-
anism explaining the increased EDV observed in the
HF- group. Indeed, these rats with normal weight obes-
ity displayed an improved EDV which was strictly due to
an increased ECVA, which was probably due to in-
creased NOS signaling as shown by the results of the L-
NAME experiments. Since the content of AA of myocar-
dial phospholipids was increased in that group and not
in the HF+ group, we also suspected the involvement of
COX products in order to explain the increased ECVA.
Indeed, indomethacin decreased the EDV of the HF-rats
but not significantly, indicating that the NOS pathway re-
mains the prominent pathway for the vasodilatation to-
gether with the activity of the endothelial cells. This
relationship between NOS/COX pathways and endothe-
lial/smooth muscle cells in the EDV seems to be reversed
in the HF+ group, with the COX pathway having the most
important role and the smooth muscle cells becoming
more sensitive. Thus, the adipose tissue distribution seems
to affect the mechanism through which the increased ACh
response occurs in the HF-fed rats.
Conclusions
In summary, our results showed that HF contribute to an
augmentation of coronary EDV, which supports an im-
proved cardiac mechanical activity necessary for the
higher whole body energy expenditure of the individuals.
Since the HF diet-fed rats did not display necessarily an
increased body weight but had systematically a higher ab-
dominal adiposity, the improved EDV was rather related
to the increased abdominal fat mass. Despite all these al-
terations, the coronary microvasculature of HF fed obese
rats adapts resulting to enhanced ACh responses in order
to maintain an adequate tissue perfusion in cases of
physiological processes of enhanced metabolic demand
such as exercise. One of the most interesting points of our
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study is that the mechanisms of the coronary reactivity re-
sponsible for the improvement of the cardiac function de-
pend on the percentage of body adiposity. Indeed, the
augmented coronary reactivity of the HF rats was due ei-
ther to an augmented sensitivity of the SMCs to NO in
the rats displaying body weight gain compared to the con-
trol ones or to an improved ECVA in the animals with no
body weight gain. To our knowledge, the last effect was
never described in the literature and our results indicate
that this was related to an enrichment of the myocardial
membranes in AA. The increased arachidonic acid propor-
tion resulted from a stimulation of elongases and inhibition
of desaturases and was responsible for an increased produc-
tion of cyclooxygenase end-product(s) with vasodilatation
properties. Whatever the mechanism through which it oc-
curs, the HF diet-induced increase in coronary reserve seem
to favor the cardiac mechanical activity and thus the up-
holding of tissue perfusion and welfare of obese individuals.
Abbreviations
AAT: Abdominal adipose tissue; Ach: Acetylcholine; ANOVA: Analysis of
variance; ATP: Adenosine triphosphate; C: Control; C1: C2, C3 and C4,
respiratory chain complexes 1, 2, 3 and 4; C16:1 n-7: Palmitoleic acid;
C18:0: Stearic acid; C18:1 n-7: Cis-vaccenic acid; C18:1 n-9: Oleic acid; C18:2
n-6: Linoleic acid; C20:2 n-6: 11,14-eicosadienoic acid; C20:3 n-6: Dihomo-
gamma-linolenic acid; C20:4 n-6 or AA: Arachidonic acid; C22:0: Behenic
acid; C22:4 n-6: Adrenic acid; C22:5 n-6: Docosapentaenoic acid; C22:5
n-3: Clupanodonic acid; CaCl2: Calcium chlorure; CO2: Carbon dioxide;
COX: Cyclooxygenase; DMA: Dimethylacetal; dP/dt max: Rate of left
ventricle pressure rise; dP/dt min: Rate of left ventricle pressure decrease;
ECs: Endothelial cells; ECVA: Endothelial cell vasodilatation activity;
EDV: Endothelial-dependent vasodilation; EIV: Endothelial-independent
vasodilatation; HF: High fat; HF-: High fat diet-fed rats with increased
abdominal adiposity and maintained body weight; HF+: High fat diet-fed
rats with increased abdominal adiposity and body weight; IR: Insulin
resistance; KCl: Potassium chlorure; KH2PO4: Potassium
dihydrogenophosphate; L-NAME: L-nitro-arginine-methyl-ester; LSD: Least
significant difference; LVDP: Left ventricular developed pressure;
MgSO4: Magnesium sulfate; MUFAs: Monounsaturated fatty acids;
NaCl: Sodium chlorure; NaHCO3: Sodium hydrogenocarbonate; NO: Nitric oxide;
NOS: Nitric oxide synthase; OGTT: Oral glucose tolerance test; O2: Dioxygen;
P: Probability; PRAT: Peri-renal adipose tissue; PUFAs: Polyunsaturated fatty acids;
RPP: Rate pressure product; SFAs: Saturated fatty acids; SMCs: Smooth muscle cells;
SNP: Sodium nitroprusside; VAT: Visceral adipose tissue; ZDF: Zucker diabetic fatty.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
'Evangelia Mourmoura conducted the experiments and contributed to the
study implementation, statistical analysis, interpretation, and the preparation
of the manuscript. Valerie Chaté conducted the in vivo experiments and Karine
Couturier the OGTT. Brigitte Laillet, Jean-Paul Rigaudière and Béatrice Morio
performed the analysis of the fatty acid composition of cardiac phospholipids.
Guillaume Vial participated in the animal care. Corinne Malpuech-Brugère and
Kasra Azarnoush helped to conduct the experiments and acquire data. Luc
Demaison supervised the study conduction and contributed to the study
conception and design, implementation, statistical interpretation, the
preparation and finalization of the manuscript. All authors approved the
final manuscript for publication.
Acknowledgments
The authors are grateful to Mr. Christophe Cottet for carefully editing the
manuscript and Cindy Tellier for animal care. This work was supported by
the French National Institute of Agronomical Research (INRA) and the French
National Institute of Health and Medical Research (INSERM).
Author details
1Université Joseph Fourier, Laboratoire de Bioénergétique Fondamentale et
Appliquée, BP 53, Grenoble F-38041, France. 2U1055 INSERM, Grenoble
F-38041, France. 3INRA, UMR 1019 Nutrition Humaine, CRNH Auvergne,
Clermont-Ferrand, France. 4Clermont Université, Université d’Auvergne, UMR
1019 Nutrition Humaine, Clermont-Ferrand, France. 5INSERM UMR-1060,
Laboratoire CarMeN, Université Lyon 1, INRA USC1362, INSA de Lyon,
Facultés de médecine Rockefeller et Charles Merieux Lyon-Sud, Lyon
F-69003, France. 6Heart surgery Department, G. Montpied Hospital,
Clermont-Ferrand University Hospital, Clermont-Ferrand, France.
Received: 6 December 2013 Accepted: 19 February 2014
Published: 27 February 2014
References
1. Coelho DF, Pereira-Lancha LO, Chaves DS, Diwan D, Ferraz R, Campos-Ferraz PL,
Poortmans JR, Lancha Junior AH: Effect of high-fat diets on body composition,
lipid metabolism and insulin sensitivity, and the role of exercise on these pa-
rameters. Adv Physiol Educ 2011, 44(10):966–972.
2. Gallagher EJ, Leroith D, Karnieli E: Insulin resistance in obesity as the
underlying cause for the metabolic syndrome. Mt. Sinai J. Med. N Y 2010,
77(5):511–523.
3. Abel ED: Myocardial insulin resistance and cardiac complications of
diabetes. Curr Drug Targets Immune Endocr Metab Disord 2005, 5(2):219–226.
4. Daly ME, Vale C, Walker M, Alberti KG, Mathers JC: Dietary carbohydrates
and insulin sensitivity: a review of the evidence and clinical implications.
Am J Clin Nutr 1997, 66(5):1072–1085.
5. Tiwari S, Ndisang JF: The role of obesity in cardiomyopathy and
nephropathy. Curr Pharm Des 2013:. [Epub ahead of print].
6. Mourmoura E, Vial G, Laillet B, Rigaudiere JP, Hininger-Favier I, Dubouchaud
H, Morio B, Demaison L: Preserved endothelium-dependent dilatation of
the coronary microvasculature at the early phase of diabetes mellitus
despite the increased oxidative stress and depressed cardiac mechanical
function ex vivo. Cardiovasc Diabetol 2013, 12:49.
7. Habbout A, Delemasure S, Goirand F, Guilland JC, Chabod F, Sediki M,
Rochette L, Vergely C: Postnatal overfeeding in rats leads to moderate
overweight and to cardiometabolic and oxidative alterations in
adulthood. Biochimie 2012, 94(1):117–124.
8. Habbout A, Guenancia C, Lorin J, Rigal E, Fassot C, Rochette L, Vergely C:
Postnatal overfeeding causes early shifts in gene expression in the heart
and long-term alterations in cardiometabolic and oxidative parameters.
PloS one 2013, 8(2):e56981.
9. Lancel S, Montaigne D, Marechal X, Marciniak C, Hassoun SM, Decoster B,
Ballot C, Blazejewski C, Corseaux D, Lescure B, Motterlini R, Neviere R:
Carbon monoxide improves cardiac function and mitochondrial
population quality in a mouse model of metabolic syndrome. PloS One
2012, 7(8):e41836.
10. Ellis A, Cheng ZJ, Li Y, Jiang YF, Yang J, Pannirselvam M, Ding H, Hollenberg
MD, Triggle CR: Effects of a Western diet versus high glucose on
endothelium-dependent relaxation in murine micro- and macro-
vasculature. Eur J Pharmacol 2008, 601(1–3):111–117.
11. Jebelovszki E, Kiraly C, Erdei N, Feher A, Pasztor ET, Rutkai I, Forster T, Edes I,
Koller A, Bagi Z: High-fat diet-induced obesity leads to increased NO
sensitivity of rat coronary arterioles: role of soluble guanylate cyclase
activation. Am J Physiol Heart Circ Physiol 2008, 294(6):H2558–H2564.
12. Franke R, Yang Y, Rubin LJ, Magliola L, Jones AW: High-fat diet alters
K +−currents in porcine coronary arteries and adenosine sensitivity during
metabolic inhibition. J Cardiovasc Pharmacol 2004, 43(4):495–503.
13. Granado M, Fernandez N, Monge L, Carreno-Tarragona G, Figueras JC, Amor S,
Garcia-Villalon AL: Long-term effects of early overnutrition in the heart of male
adult rats: role of the renin-angiotensin system. PloS One 2013, 8(6):e65172.
14. Galili O, Versari D, Sattler KJ, Olson ML, Mannheim D, McConnell JP, Chade
AR, Lerman LO, Lerman A: Early experimental obesity is associated with
coronary endothelial dysfunction and oxidative stress. Am J Physiol Heart
Circ Physiol 2007, 292(2):H904–H911.
15. Yang Y, Jones AW, Thomas TR, Rubin LJ: Influence of sex, high-fat diet,
and exercise training on potassium currents of swine coronary smooth
muscle. Am J Physiol Heart Circ Physiol 2007, 293(3):H1553–H1563.
16. Kume T, Kawamoto T, Okura H, Neishi Y, Hashimoto K, Hayashida A,
Watanabe N, Kanda Y, Mochizuki S, Goto M, Yoshida K: Evaluation of
coronary endothelial function by catheter-type NO sensor in
Mourmoura et al. Cardiovascular Diabetology 2014, 13:54 Page 11 of 12
http://www.cardiab.com/content/13/1/54
high-fat-diet-induced obese dogs. Circ J Official J Japanese Circ Soc 2009,
73(3):562–567.
17. Park Y, Booth FW, Lee S, Laye MJ, Zhang C: Physical activity opposes
coronary vascular dysfunction induced during high fat feeding in mice.
J Physiol 2012, 590(Pt 17):4255–4268.
18. La Favor JD, Anderson EJ, Hickner RC, Wingard CJ: Erectile dysfunction
precedes coronary artery endothelial dysfunction in rats fed a high-fat,
high-sucrose, Western pattern diet. J Sexual Med 2013, 10(3):694–703.
19. Wilkes JJ, Bonen A, Bell RC: A modified high-fat diet induces insulin
resistance in rat skeletal muscle but not adipocytes. Am J Physiol 1998,
275(4 Pt 1):E679–E686.
20. Dobrian AD, Davies MJ, Prewitt RL, Lauterio TJ: Development of
hypertension in a rat model of diet-induced obesity. Hypertension 2000,
35(4):1009–1015.
21. Cortez MY, Torgan CE, Brozinick JT Jr, Ivy JL: Insulin resistance of obese
Zucker rats exercise trained at two different intensities. Am J Physiol 1991,
261(5 Pt 1):E613–E619.
22. Mourmoura E, Leguen M, Dubouchaud H, Couturier K, Vitiello D, Lafond JL,
Richardson M, Leverve X, Demaison L: Middle age aggravates myocardial
ischemia through surprising upholding of complex II activity, oxidative
stress, and reduced coronary perfusion. Age (Dordr) 2011, 33(3):321–336.
23. Faloona GR, Srere PA: Escherichia coli citrate synthase. Purification and the
effect of potassium on some properties. Biochemistry 1969, 8(11):4497–4503.
24. Demaison L, Grynberg A: Influence of dietary linseed oil and sunflower
seed oil on some mechanical and metabolic parameters of isolated
working rat hearts. Reprod Nutr Dev 1991, 31(1):37–45.
25. Folch J, Lees M, Sloane Stanley GH: A simple method for the isolation and
purification of total lipides from animal tissues. J Biol Chem 1957,
226(1):497–509.
26. Juaneda P, Rocquelin G, Astorg PO: Separation and quantification of heart
and liver phospholipid classes by high-performance liquid chromatog-
raphy using a new light-scattering detector. Lipids 1990, 25(11):756–759.
27. Fontana L: [Nutrition, adiposity and health]. Epidemiologia e prevenzione
2007, 31(5):290–294.
28. Romero-Corral A, Somers VK, Sierra-Johnson J, Korenfeld Y, Boarin S, Korinek
J, Jensen MD, Parati G, Lopez-Jimenez F: Normal weight obesity: a risk
factor for cardiometabolic dysregulation and cardiovascular mortality.
Eur Heart J 2010, 31(6):737–746.
29. Cole MA, Murray AJ, Cochlin LE, Heather LC, McAleese S, Knight NS, Sutton E,
Jamil AA, Parassol N, Clarke K: A high fat diet increases mitochondrial fatty
acid oxidation and uncoupling to decrease efficiency in rat heart. Basic Res
Cardiol 2011, 106(3):447–457.
30. Buettner R, Parhofer KG, Woenckhaus M, Wrede CE, Kunz-Schughart LA,
Scholmerich J, Bollheimer LC: Defining high-fat-diet rat models: metabolic
and molecular effects of different fat types. J Mol Endocrinol 2006,
36(3):485–501.
31. van den Brom CE, Bulte CS, Kloeze BM, Loer SA, Boer C, Bouwman RA:
High fat diet-induced glucose intolerance impairs myocardial function,
but not myocardial perfusion during hyperaemia: a pilot study.
Cardiovasc Diabetol 2012, 11:74.
32. Beasley JM, Wertheim BC, LaCroix AZ, Prentice RL, Neuhouser ML, Tinker LF,
Kritchevsky S, Shikany JM, Eaton C, Chen Z, Thomson CA: Biomarker-
calibrated protein intake and physical function in the Women's Health
Initiative. J Am Geriatr Soc 2013, 61(11):1863–1871.
33. Drummond MJ, Dreyer HC, Pennings B, Fry CS, Dhanani S, Dillon EL,
Sheffield-Moore M, Volpi E, Rasmussen BB: Skeletal muscle protein
anabolic response to resistance exercise and essential amino acids is
delayed with aging. J Appl Physiol (1985) 2008, 104(5):1452–1461.
34. Paddon-Jones D, Rasmussen BB: Dietary protein recommendations and
the prevention of sarcopenia. Curr Opin Clin Nutr Metab Care 2009,
12(1):86–90.
35. Symons TB, Schutzler SE, Cocke TL, Chinkes DL, Wolfe RR, Paddon-Jones D:
Aging does not impair the anabolic response to a protein-rich meal.
Am J Clin Nutr 2007, 86(2):451–456.
36. Hunte C, Richers S: Lipids and membrane protein structures. Curr Opin
Struc Biol 2008, 18(4):406–411.
37. Abeywardena MY, McLennan PL, Charnock JS: Differential effects of dietary
fish oil on myocardial prostaglandin I2 and thromboxane A2 production.
Am J Physiol 1991, 260(2 Pt 2):H379–H385.
38. Rupp H, Wagner D, Rupp T, Schulte LM, Maisch B: Risk stratification by the
"EPA + DHA level" and the "EPA/AA ratio" focus on anti-inflammatory
and antiarrhythmogenic effects of long-chain omega-3 fatty acids.
Herz 2004, 29(7):673–685.
39. Cheng Y, Li W, McElfresh TA, Chen X, Berthiaume JM, Castel L, Yu X, Van
Wagoner DR, Chandler MP: Changes in myofilament proteins, but not Ca(2)
(+) regulation, are associated with a high-fat diet-induced improvement in
contractile function in heart failure. Am J Physiol Heart Circ Physiol 2011,
301(4):H1438–H1446.
40. Christopher BA, Huang HM, Berthiaume JM, McElfresh TA, Chen X, Croniger
CM, Muzic RF Jr, Chandler MP: Myocardial insulin resistance induced by
high fat feeding in heart failure is associated with preserved contractile
function. Am J Physiol Heart Circ Physiol 2010, 299(6):H1917–H1927.
41. Haynes WG, Morgan DA, Walsh SA, Sivitz WI, Mark AL: Cardiovascular
consequences of obesity: role of leptin. Clin Exp Pharmacol Physiol 1998,
25(1):65–69.
42. Nedvidkova J, Smitka K, Kopsky V, Hainer V: Adiponectin, an adipocyte-
derived protein. Physiol Res/Academia Scientiarum Bohemoslovaca 2005,
54(2):133–140.
43. Frohlich ED: Obesity and hypertension. Hemodynamic aspects. Ann
Epidemiol 1991, 1(4):287–293.
44. Kenchaiah S, Narula J, Vasan RS: Risk factors for heart failure. Med Clin
North Am 2004, 88(5):1145–1172.
45. Lavie CJ, Messerli FH: Cardiovascular adaptation to obesity and
hypertension. Chest 1986, 90(2):275–279.
46. Cai H, Harrison DG: Endothelial dysfunction in cardiovascular diseases:
the role of oxidant stress. Circ Res 2000, 87(10):840–844.
47. Bagi Z: Mechanisms of coronary microvascular adaptation to obesity.
Am J Physiol Regul Integr Comp Physiol 2009, 297(3):R556–R567.
48. Tune JD, Gorman MW, Feigl EO: Matching coronary blood flow to
myocardial oxygen consumption. J Appl Physiol (1985) 2004, 97(1):404–415.
49. Baber SR, Deng W, Rodriguez J, Master RG, Bivalacqua TJ, Hyman AL,
Kadowitz PJ: Vasoactive prostanoids are generated from arachidonic acid
by COX-1 and COX-2 in the mouse. Am J Physiol Regul Integr Comp Physiol
2005, 289(4):H1476–H1487.
doi:10.1186/1475-2840-13-54
Cite this article as: Mourmoura et al.: Body adiposity dictates different
mechanisms of increased coronary reactivity related to improved in vivo
cardiac function. Cardiovascular Diabetology 2014 13:54.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Mourmoura et al. Cardiovascular Diabetology 2014, 13:54 Page 12 of 12
http://www.cardiab.com/content/13/1/54
